The amount of Fusobacterium nucleatum DNA in colorectal cancer tissue in relation to combined MSI/CIMP/BRAF status
| Combined MSI/CIMP/BRAF status | The amount of F. nucleatum DNA | |||||
|---|---|---|---|---|---|---|
| MSI status | CIMP status | BRAF mutation | All patients (n=953) | Negative (n=833) | Low (n=59) | High (n=61) |
| High | High | Mutant | 83 | 56 (67%) | 10 (12%) | 17 (21%) |
| High | High | Wild type | 37 | 29 (78%) | 2 (5.4%) | 6 (16%) |
| High | Low/negative | Mutant | 3 | 1 (33%) | 1 (33%) | 1 (33%) |
| High | Low/negative | Wild type | 32 | 21 (66%) | 6 (19%) | 5 (15%) |
| MSI-low/MSS | High | Mutant | 29 | 27 (93%) | 0 | 2 (6.9%) |
| MSI-low/MSS | High | Wild type | 27 | 25 (93%) | 1 (3.7%) | 1 (3.7%) |
| MSI-low/MSS | Low/negative | Mutant | 40 | 38 (95%) | 1 (2.5%) | 1 (2.5%) |
| MSI-low/MSS | Low/negative | Wild type | 702 | 636 (91%) | 38 (5.4%) | 28 (4.0%) |
Percentage indicates the proportion of F. nucleatum-negative, F. nucleatum-low or F. nucleatum-high cases among all cases with a given specific combined MSI/CIMP/BRAF status.
CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable.